BSECompany UpdateInsolvency24 Oct 2026
Kobo Biotech Ltd-$
Order of NCLT
Kobo Biotech Ltd has informed BSE that the Hon'ble NCLT has appointed Mr. Rajat Mukherjee as the Chairman of the Monitoring Committee, in place of Ms. Namrata Amol Randeri, Resolution Professional, who had tendered her resignation.
BSECompany UpdateRegulatory15 Oct 2026
Kobo Biotech Ltd-$
Certificate under Reg. 74(5)of SEBI (DP)30.09.2026
Kobo Biotech Ltd has submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming compliance for the quarter ended 30th September, 2026.
BSEAGM/EGM24 Jul 2026
Kobo Biotech Ltd-$
outcome, summary proceddings and scrutinizer reprot of 32nd AGM for 31. 03.2025 on VC/OAVM
Kobo Biotech Ltd held its 32nd Annual General Meeting on July 24, 2026, with 41 shareholders present through video conferencing. The meeting adopted the annual accounts and reports for the financial year ended March 31, 2025, with 100% of votes in favour. The meeting was concluded at 11:06 a.m.
BSEAGM/EGM24 Jul 2026
Kobo Biotech Ltd-$
Proceedings of 32nd AGM for 31.03.2025 with reports and voting results.
Kobo Biotech Ltd held its 32nd Annual General Meeting on July 24, 2026, with 41 shareholders present, including 0 promoters and 41 public shareholders. The meeting approved the annual accounts and reports for the financial year ended March 31, 2025, with 100% of votes in favour.
BSEAGM/EGM24 Jul 2026
Kobo Biotech Ltd-$
Scrtnizer report for AGM held for 31.03.2024
Kobo Biotech Ltd held its 31st Annual General Meeting on July 24, 2026, with 35 shareholders present through video conferencing. The meeting adopted the annual accounts and reports for the financial year ended March 31, 2024, with 100% of votes cast in favor. The company provided a summary of the proceedings and the voting results.
BSEAGM/EGM24 Jul 2026
Kobo Biotech Ltd-$
Outcome of shareholder meeting held thorugh VC/OAVM for 31.03.2024
Kobo Biotech Ltd held its 31st Annual General Meeting on July 24, 2026, where the adoption of annual accounts and reports for the financial year ended March 31, 2024, was approved by shareholders. The meeting was conducted through video conferencing and had a total of 35 shareholders present, with 17934 votes cast in favor of the resolution.